BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 27034161)

  • 1. Genetic and epigenetic factors affect RET gene expression in breast cancer cell lines and influence survival in patients.
    Griseri P; Garrone O; Lo Sardo A; Monteverde M; Rusmini M; Tonissi F; Merlano M; Bruzzi P; Lo Nigro C; Ceccherini I
    Oncotarget; 2016 May; 7(18):26465-79. PubMed ID: 27034161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of RET is associated with Oestrogen receptor expression but lacks prognostic significance in breast cancer.
    Mechera R; Soysal SD; Piscuoglio S; Ng CKY; Zeindler J; Mujagic E; Däster S; Glauser P; Hoffmann H; Kilic E; Droeser RA; Weber WP; Muenst S
    BMC Cancer; 2019 Jan; 19(1):41. PubMed ID: 30621641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RET in breast cancer: pathogenic implications and mechanisms of drug resistance.
    Lo Nigro C; Rusmini M; Ceccherini I
    Cancer Drug Resist; 2019; 2(4):1136-1152. PubMed ID: 35582269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
    Simigdala N; Gao Q; Pancholi S; Roberg-Larsen H; Zvelebil M; Ribas R; Folkerd E; Thompson A; Bhamra A; Dowsett M; Martin LA
    Breast Cancer Res; 2016 Jun; 18(1):58. PubMed ID: 27246191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ret Receptor Has Distinct Alterations and Functions in Breast Cancer.
    Gattelli A; Hynes NE; Schor IE; Vallone SA
    J Mammary Gland Biol Neoplasia; 2020 Mar; 25(1):13-26. PubMed ID: 32080788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
    Raha P; Thomas S; Thurn KT; Park J; Munster PN
    Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High expression of the RET receptor tyrosine kinase and its ligand GDNF identifies a high-risk subset of estrogen receptor positive breast cancer.
    Kakati RT; Kim H; Whitman A; Spanheimer PM
    Breast Cancer Res Treat; 2023 Jun; 199(3):589-601. PubMed ID: 37061618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of transcription factor AP-2 gamma with proto-oncogene PELP1 promotes tumorigenesis by enhancing RET signaling.
    Liu J; Liu Z; Li M; Tang W; Pratap UP; Luo Y; Altwegg KA; Li X; Zou Y; Zhu H; Sareddy GR; Viswanadhapalli S; Vadlamudi RK
    Mol Oncol; 2021 Apr; 15(4):1146-1161. PubMed ID: 33269540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A role of SIPL1/SHARPIN in promoting resistance to hormone therapy in breast cancer.
    Ojo D; Wu Y; Bane A; Tang D
    Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):735-745. PubMed ID: 29248549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Ret receptor tyrosine kinase pathway functionally interacts with the ERalpha pathway in breast cancer.
    Boulay A; Breuleux M; Stephan C; Fux C; Brisken C; Fiche M; Wartmann M; Stumm M; Lane HA; Hynes NE
    Cancer Res; 2008 May; 68(10):3743-51. PubMed ID: 18483257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
    Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S
    Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
    Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
    Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit.
    Spitschak A; Meier C; Kowtharapu B; Engelmann D; Pützer BM
    Mol Cancer; 2017 Jan; 16(1):24. PubMed ID: 28122586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of an estrogen-regulated variant transcript of the peroxisomal branched chain fatty acid oxidase ACOX2 in breast carcinomas.
    Bjørklund SS; Kristensen VN; Seiler M; Kumar S; Alnæs GI; Ming Y; Kerrigan J; Naume B; Sachidanandam R; Bhanot G; Børresen-Dale AL; Ganesan S
    BMC Cancer; 2015 Jul; 15():524. PubMed ID: 26183823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease.
    Liu J; Prager-van der Smissen WJ; Look MP; Sieuwerts AM; Smid M; Meijer-van Gelder ME; Foekens JA; Hollestelle A; Martens JW
    Cancer Lett; 2016 Jun; 376(1):104-9. PubMed ID: 27018307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A newly identified RET proto-oncogene polymorphism is found in a high number of endocrine tumor patients.
    Gartner W; Mineva I; Daneva T; Baumgartner-Parzer S; Niederle B; Vierhapper H; Weissel M; Wagner L
    Hum Genet; 2005 Jul; 117(2-3):143-53. PubMed ID: 15841388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting RET-interleukin-6 crosstalk to impair metastatic dissemination in breast cancer.
    Morandi A; Isacke CM
    Breast Cancer Res; 2014 Jan; 16(1):301. PubMed ID: 24467886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
    Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
    Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo application of radiolabeled gastrin-releasing peptide receptor ligands in breast cancer.
    Dalm SU; Martens JW; Sieuwerts AM; van Deurzen CH; Koelewijn SJ; de Blois E; Maina T; Nock BA; Brunel L; Fehrentz JA; Martinez J; de Jong M; Melis M
    J Nucl Med; 2015 May; 56(5):752-7. PubMed ID: 25791989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.